How the federal Medicare program pays — or doesn't — for GLP-1 medications. By law Medicare has been barred from covering drugs used purely for weight loss, though it does cover them for diabetes and certain other approved uses (such as cardiovascular risk reduction and sleep apnea). That's now shifting: a temporary CMS demonstration, the Medicare GLP-1 Bridge, covers Wegovy, Zepbound, and Foundayo for obesity at a flat $50/month copay for eligible Part D members from July 1, 2026 through December 31, 2027 — though the underlying statutory weight-loss exclusion still stands. For the 50-and-over audience this is often the single biggest cost question, so verify current specifics for your plan.
Related terms: Formulary · Prior authorization (PA) · Copay card / manufacturer savings program · True cost (all-in pricing)
See also: True monthly cost calculator